Health Catalyst, Inc. (NASDAQ:HCAT) Shares Sold by Charles Schwab Investment Management Inc.

Charles Schwab Investment Management Inc. reduced its holdings in shares of Health Catalyst, Inc. (NASDAQ:HCAT) by 5.6% during the 3rd quarter, HoldingsChannel reports. The institutional investor owned 573,061 shares of the company’s stock after selling 33,710 shares during the quarter. Charles Schwab Investment Management Inc.’s holdings in Health Catalyst were worth $4,665,000 as of its most recent SEC filing.

Several other hedge funds also recently added to or reduced their stakes in the business. Primecap Management Co. CA increased its holdings in shares of Health Catalyst by 14.7% in the second quarter. Primecap Management Co. CA now owns 2,379,462 shares of the company’s stock valued at $15,205,000 after purchasing an additional 305,079 shares during the period. Janney Montgomery Scott LLC acquired a new stake in Health Catalyst during the third quarter worth about $897,000. Essex Investment Management Co. LLC acquired a new stake in Health Catalyst during the third quarter worth about $2,012,000. AQR Capital Management LLC purchased a new position in Health Catalyst during the second quarter worth approximately $564,000. Finally, Impax Asset Management Group plc boosted its position in Health Catalyst by 16.4% during the third quarter. Impax Asset Management Group plc now owns 2,554,475 shares of the company’s stock worth $20,793,000 after purchasing an additional 360,201 shares in the last quarter. 85.00% of the stock is owned by institutional investors and hedge funds.

Health Catalyst Trading Down 0.2 %

Shares of NASDAQ HCAT opened at $7.99 on Friday. Health Catalyst, Inc. has a twelve month low of $5.42 and a twelve month high of $11.41. The company has a current ratio of 1.41, a quick ratio of 1.41 and a debt-to-equity ratio of 0.32. The stock has a fifty day simple moving average of $8.16 and a 200-day simple moving average of $7.43. The stock has a market capitalization of $486.18 million, a PE ratio of -5.92 and a beta of 1.31.

Health Catalyst (NASDAQ:HCAT) last released its earnings results on Wednesday, November 6th. The company reported $0.07 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.10 by ($0.03). The company had revenue of $76.40 million during the quarter, compared to analysts’ expectations of $76.27 million. Health Catalyst had a negative net margin of 26.20% and a negative return on equity of 7.51%. The company’s revenue for the quarter was up 3.5% on a year-over-year basis. During the same quarter last year, the business posted ($0.22) earnings per share. On average, equities analysts forecast that Health Catalyst, Inc. will post -0.33 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several equities analysts have recently weighed in on the company. Citigroup raised their target price on Health Catalyst from $9.00 to $10.50 and gave the company a “buy” rating in a research report on Wednesday, November 13th. Royal Bank of Canada lifted their price objective on Health Catalyst from $8.00 to $9.00 and gave the stock a “sector perform” rating in a research report on Thursday, November 7th. Piper Sandler reiterated an “overweight” rating and set a $12.00 price objective (up previously from $11.00) on shares of Health Catalyst in a research report on Tuesday, November 26th. Evercore ISI lifted their price objective on Health Catalyst from $8.00 to $10.00 and gave the stock an “outperform” rating in a research report on Tuesday, October 8th. Finally, Cantor Fitzgerald reissued an “overweight” rating and set a $16.00 target price on shares of Health Catalyst in a research note on Friday, October 4th. Three equities research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the stock. According to data from MarketBeat.com, Health Catalyst currently has an average rating of “Moderate Buy” and an average target price of $11.79.

Insider Activity at Health Catalyst

In other Health Catalyst news, insider Kevin Lee Freeman sold 7,500 shares of Health Catalyst stock in a transaction dated Monday, December 2nd. The stock was sold at an average price of $8.94, for a total transaction of $67,050.00. Following the completion of the sale, the insider now directly owns 236,950 shares of the company’s stock, valued at $2,118,333. The trade was a 3.07 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, CFO Jason Alger sold 19,599 shares of Health Catalyst stock in a transaction dated Friday, December 6th. The stock was sold at an average price of $8.32, for a total value of $163,063.68. Following the sale, the chief financial officer now directly owns 86,712 shares of the company’s stock, valued at $721,443.84. This trade represents a 18.44 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders sold 59,433 shares of company stock worth $492,503. Company insiders own 2.50% of the company’s stock.

Health Catalyst Profile

Health Catalyst, Inc provides data and analytics technology and services to healthcare organizations in the United States. It operates in two segments, Technology and Professional Services. The company provides data operating system data platform which provides clients single comprehensive environment to integrate and organize data from their disparate software systems; and analytics applications, a software analytics applications build for data platform to analyze clients face across clinical and quality, population health, and financial and operational use cases.